Biotech RadarJobs updated

COMPANY

Io Therapeutics, Inc.

HQ: Houston, TX source · io-therapeutics.com ↗ · Southwest

Clinical Phase 2

Keywords: small molecule oncology neurology immunology neurodegenerative diseases autoimmune diseases her2-positive breast cancer Psoriasis Plaque Type Psorisis Plaque Psoriasis Nonsmall Cell Lung Cancer Castration Resistant Prostate Cancer Parkinson's Disease IRX4204 NRX 194204

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis source ↗
  2. Trial start Phase 1: Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC source ↗
  3. Trial start Phase 1: Study of IRX4204 for Treatment of Early Parkinson's Disease source ↗
  4. Trial start Phase 2: Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06723171Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque PsoriasisPhase 2SuspendedMar 1, 20262026-03 (estimated)
NCT02991651Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCPhase 1TerminatedDec 7, 2016May 9, 2025 (actual)
NCT01540071Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate CancerPhase 2Completed2011-082015-12 (actual)
NCT02438215Study of IRX4204 for Treatment of Early Parkinson's DiseasePhase 1Completed2014-082015-05 (actual)
Feedback